Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances

Series type: Risk assessments

Summary

This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • Europol–EMCDDA Joint Report on CUMYL-4CN-BINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) — a summary
  • Risk Assessment Report on a new psychoactive substance: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
  • Technical report on 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
  • Participants of the risk assessment meeting, 7-8 November 2017

Council Implementing Decision on subjecting CUMYL-4CN-BINACA to control measures

Pages: 
60
Price: 
Free
ISBN: 
978-92-9497-291-0
ISSN: 
1725-4493
Pub. DOI: 
10.2810/408735
Catalog Number: 
TDAK18002ENN
Loading